XSTOQLIFE
Market cap1mUSD
Dec 23, Last price
2.20SEK
1D
3.77%
1Q
-13.39%
IPO
-76.82%
Name
Qlife Holding AB
Chart & Performance
P/E
—
P/S
63.66
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
17.54%
Revenues
244k
-98.64%
Net income
-160m
L+71.74%
CFO
-42m
L-12.43%
Earnings
Jun 26, 2025
Profile
Qlife Holding AB (publ), a med-tech company, manufactures and sells in-vitro diagnostic analyzers and reagents. The company offers Egoo.Health Platform, an integrated platform with a measuring instrument with disposable capsules and software, where each capsule contains a test for a specific biomarker or virus. Its biomarkers include C-reactive protein home-testing capsule, PHE/Phenylalanine for PKU patients, and Sars-CoV-2/Influenza multiplex for virus/bacteria tests. The company was incorporated in 2019 and is based in Helsingborg, Sweden.
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | 244 -98.64% | 17,993 -54.58% | 39,613 90.91% | ||
Cost of revenue | 110,319 | (17,926) | 41,088 | ||
Unusual Expense (Income) | |||||
NOPBT | (110,075) | 35,919 | (1,475) | ||
NOPBT Margin | 199.63% | ||||
Operating Taxes | (4,738) | (7,860) | (7,503) | ||
Tax Rate | |||||
NOPAT | (105,337) | 43,779 | 6,028 | ||
Net income | (159,956) 71.74% | (93,141) 140.07% | (38,797) 92.06% | ||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 61,777 | 53,113 | 120,844 | ||
BB yield | -1,021,850.59% | -49,942.85% | -8,021.23% | ||
| Debt | |||||
Debt current | 12,564 | 4,148 | 939 | ||
Long-term debt | 13,875 | 97,722 | 3,510 | ||
Deferred revenue | 2,534 | ||||
Other long-term liabilities | 2 | (2,763) | |||
Net debt | 24,778 | 87,323 | (74,216) | ||
| Cash flow | |||||
Cash from operating activities | (41,798) | (47,733) | (26,051) | ||
CAPEX | (594) | (42,940) | (26,768) | ||
Cash from investing activities | (20,840) | (42,940) | (26,768) | ||
Cash from financing activities | 48,997 | 32,726 | 105,419 | ||
FCF | (33,552) | 14,999 | (14,936) | ||
| Balance | |||||
Cash | 1,661 | 14,547 | 73,461 | ||
Long term investments | 5,204 | ||||
Excess cash | 1,649 | 13,647 | 76,684 | ||
Stockholders' equity | (253,395) | (134,013) | (72,745) | ||
Invested Capital | 250,517 | 277,605 | 239,397 | ||
ROIC | 16.94% | 3.36% | |||
ROCE | 3,824.70% | 25.01% | |||
| EV | |||||
Common stock shares outstanding | 304 | 53 | 45 | ||
Price | 0.02 -99.00% | 2.00 -94.01% | 33.35 43.75% | ||
Market cap | 6 -94.32% | 106 -92.94% | 1,507 73.98% | ||
EV | 24,784 | 87,429 | (72,709) | ||
EBITDA | (103,310) | 53,990 | 7,338 | ||
EV/EBITDA | 1.62 | ||||
Interest | 7,426 | 4,881 | 1,404 | ||
Interest/NOPBT | 13.59% | ||||